Midgut barriers prevent the replication and dissemination of the yellow fever vaccine in Aedes aegypti

Danet, Lucie; Beauclair, Guillaume; Berthet, Michèle; Moratorio, Gonzalo; Gracias, Ségolène; Tangy, Frédéric; Choumet, Valérie; Jouvenet, Nolwenn

doi:10.1371/journal.pntd.0007299

Cited by 23 publications

(28 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, YFV 17D and the chimeric JE vaccine IMOJEV® each have strongly reduced infection rates in both Aedes and Culex spp . mosquitoes, respectively [50,51].…”

Section: Biological Properties Of An Ideal Human Wnv Vaccinementioning

confidence: 99%

Twenty Years of Progress Toward West Nile Virus Vaccine Development

Kaiser

Barrett

2019

Viruses

View full text Add to dashboard Cite

Although West Nile virus (WNV) has been a prominent mosquito-transmitted infection in North America for twenty years, no human vaccine has been licensed. With a cumulative number of 24,714 neurological disease cases and 2314 deaths in the U.S. since 1999, plus a large outbreak in Europe in 2018 involving over 2000 human cases in 15 countries, a vaccine is essential to prevent continued morbidity, mortality, and economic burden. Currently, four veterinary vaccines are licensed, and six vaccines have progressed into clinical trials in humans. All four veterinary vaccines require multiple primary doses and annual boosters, but for a human vaccine to be protective and cost effective in the most vulnerable older age population, it is ideal that the vaccine be strongly immunogenic with only a single dose and without subsequent annual boosters. Of six human vaccine candidates, the two live, attenuated vaccines were the only ones that elicited strong immunity after a single dose. As none of these candidates have yet progressed beyond phase II clinical trials, development of new candidate vaccines and improvement of vaccination strategies remains an important area of research.

show abstract

“…Moreover, YFV 17D and the chimeric JE vaccine IMOJEV® each have strongly reduced infection rates in both Aedes and Culex spp . mosquitoes, respectively [50,51].…”

Section: Biological Properties Of An Ideal Human Wnv Vaccinementioning

confidence: 99%

Twenty Years of Progress Toward West Nile Virus Vaccine Development

Kaiser

Barrett

2019

Viruses

View full text Add to dashboard Cite

show abstract

“…Three days post oral infection, the DENV infection was restricted to the midgut tissue, with no obvious infection in other tissues. By five days PI, however, we detected viral protein not only in the midgut, but also in fat tissue, suggesting that the virus was able to cross the midgut barrier [ 22 , 23 ]. By seven days PI, we detected viral NS1 signals in muscles and salivary glands ( Figure 3 A).…”

Section: Resultsmentioning

confidence: 99%

Releasing Intracellular NS1 from Mosquito Cells for the Detection of Dengue Virus-Infected Mosquitoes

Cheng

Liu

et al. 2020

Viruses

View full text Add to dashboard Cite

Dengue virus (DENV), the pathogen that causes dengue fever, is mainly transmitted by Aedes aegypti. Surveillance of infected mosquitoes is a major component of integrated mosquito control methods for reducing the risk of vector-born disease outbreaks. However, a specialized rapid test for DENV detection in mosquitoes is not currently available. Utilizing immunoblotting, we found that the secretion of NS1 from both a DENV-infected mosquito cell line and mosquito bodies was below the detection threshold. However, when Triton X-100 was used to lyse infected mosquitoes, intracellular NS1 was released, and could then be effectively detected by the NS1 rapid test. The distribution of DENV NS1 in intrathoracically infected mosquitoes was different from that of orally infected mosquitoes. Next, we performed sensitivity tests by bisecting mosquitoes longitudinally; one half of each mosquito was subjected to the NS1 rapid test while the other half was used for qPCR confirmation. This modified test had a sensitivity of nearly 90% from five days post-infection onwards, while DENV had escaped from the midgut barrier. This adapted test offers a valuable, easy-to-use tool for mosquito surveillance, which is a crucial component of DENV disease control.

show abstract

“…A NanoDrop Spectrophotometer (ThermoFisher Scientific) was used to measure the RNA concentration of these viral samples. Previously established primers were used, as listed in Table 1, for qPCR to confirm the presence of corresponding viral RNA in the samples (43–46).…”

Section: Methodsmentioning

confidence: 99%

Field-deployable molecular diagnostic platform for arbovirus and Wolbachia detection in Aedes aegypti

Rutkowski

Dong

Dimopoulos

2020

Preprint

View full text Add to dashboard Cite

26Background: Surveillance of mosquito infection status is critical for planning and deployment 27 of proper mosquito control initiatives. Concurrently, Wolbachia is being widely used as a control 28 method for arboviral transmission. Point-of-care (POC) detection assays are necessary for 29 monitoring the infection prevalence and geographic range of viruses as well as Wolbachia in 30 mosquito vector populations. We therefore assessed the novel qPCR bCUBE molecular 31 diagnostic system as a tool for virus and Wolbachia detection. 32 Results: We developed a reliable, specific, and sensitive diagnostic assay for detecting Zika 33 virus and dengue virus serotype 2 using the real-time qPCR platform bCUBE. With bCUBE-34 based qRT-PCR, both Wolbachia bacterium and virus RNA could be reliably detected in 35 individually infected Ae. aegypti mosquitoes and in pools of 5, 10, or 15 mosquitoes. 36 Conclusions: The portable qPCR bCUBE diagnostic platform is capable of detecting Zika and 37 dengue virus as well as Wolbachia in mosquitoes and therefore has potential as a practical field-38 deployable diagnostic test for vector-borne disease surveillance programs. 39 40 41 42 43 44 45 46 47

show abstract

Midgut barriers prevent the replication and dissemination of the yellow fever vaccine in Aedes aegypti

Cited by 23 publications

References 49 publications

Twenty Years of Progress Toward West Nile Virus Vaccine Development

Twenty Years of Progress Toward West Nile Virus Vaccine Development

Releasing Intracellular NS1 from Mosquito Cells for the Detection of Dengue Virus-Infected Mosquitoes

Field-deployable molecular diagnostic platform for arbovirus and Wolbachia detection in Aedes aegypti

Contact Info

Product

Resources

About